EMD Serono (EMDS) announced that it will apply its contract pharmacy restrictions to all covered entities beginning October 1, 2024.  EMDS is allowing an exception to Ryan White Clinics for purchases of Serostim®.  Other changes are:

• Wholly Owned Contract Pharmacies: EMDS is eliminating its exception for shipments to wholly owned pharmacies.
• Geographic Restrictions: Covered entities without an in-house pharmacy may designate a single contract pharmacy but it must be located within 40 miles of the parent site.  Covered entities may designate a second contract pharmacy in EMDS’s secured distribution network for purchases of Serostim® but the pharmacy must be located within 40 miles of the parent site.

All covered entities subject to the updated EMDS policy must designate or re-designate a contract pharmacy through the 340B ESP™ platform by September 20, 2024 for it to take effect by October 1, 2024.  Covered entities that have previously designated a contract pharmacy must re-designate it by September 20, 2024 or lose access to EMD Serono products.

The Powers 340B team will continue to monitor manufacturers’ restrictive contract pharmacy policies.